Fusarium species are saprophytic molds which cause disseminated or localized infections in humans. Disseminated Fusarium infection can cause significant morbidity and mortality in immunocompromised patients. We present a case of disseminated fusariosis caused by Fusarium verticillioides in a patient with acute lymphoblastic leukemia and successfully treated using both liposomal amphotericin B and voriconazole.
CASE REPORTA 12-year-old boy underwent allogeneic hematopoietic stem cell transplant (allo-HSCT) from unrelated cord blood for high-risk acute lymphoblastic leukemia in its first complete remission. The conditioning regimen included busulfex (12.8 mg/kg of body weight), etoposide (40 mg/kg), and cyclophosphamide (120 mg/kg). For graft-versus-host-disease prophylaxis, cyclosporine A was added on day Ϫ1 but switched to mycophenolate mofetil due to severe allergic reaction. By the fourth day after the transplant, he was in severe neutropenia (Ͻ0.1 ϫ 10 3 neutrophils/l) and became febrile, and antibiotic treatment (meropenem) was initiated for febrile neutropenia. Although the fever disappeared within few days of antibiotic onset, on day 23 posttransplant, he again became febrile, and treatment with liposomal amphotericin B (LAmB) was then started, with a dosage of 3 mg/kg/day. Cultures of separate blood samples obtained percutaneously and from a central venous catheter yielded coagulase-negative Staphylococcus epidermidis, and teicoplanin was added. On day 59 posttransplant, the patient developed multiple skin lesions, starting from the extremities and spreading to the face and trunk. The lesions had necrotic centers surrounded by spreading erythema (Fig. 1). A biopsy of the skin lesion showed the presence of histopathological symptoms consistent with a septate pathogenic mold, and blood cultures taken on the same day were positive for a Fusarium species.The diagnosis of disseminated fusariosis was established, and LAmB was raised to a dose of 5 mg/kg/day. During the days following, the lesions worsened and treatment with voriconazole (loading dose, 6 mg/kg/day, followed by 4 mg/kg/day intravenously every 12 h) was initiated. A chest X-ray and a high-resolution computed tomography scan of the lungs were normal. Since profound neutropenia still continued, it was accepted that the patient had graft failure and new, unrelated donor search was started. Since a fully HLA-matched donor was not available, the patient underwent peripheral blood stem cell transplantation from a 9/10-matched, unrelated donor on day 82 posttransplant. The conditioning regimen included cyclophosphamide (120 mg/kg), and for graft-versus-host-disease prophylaxis, antithymocyte globulin (60 mg/kg), mycophenolate mofetil, and methotrexate were used. Neutrophil engraftment occurred on day 13 posttransplant. Combined-antifungal therapy and antifungal therapy with only voriconazole were continued until the ends of first and third months after peripheral blood stem cell transplantation, respectively. Two weeks after discontinuation of voriconaz...